PP_1170x120_10-25-21

Tresiba

Novo Nordisk releases Xultophy 100/3.6 insulin pen

Novo Nordisk releases Xultophy 100/3.6 insulin pen

PLAINSBORO, N.J. — Novo Nordisk has launched Xultophy 100/3.6, a combination therapy insulin pen, at pharmacies nationwide. Xultophy 100/3.6 combines the long-acting basal insulin Tresiba (insulin degludec U-100) with the No. 1-prescribed glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy Victoza (liraglutide 3.6 mg/ml) in a once-daily injection, Novo Nordisk said. The prefilled pen is indicated as

Novo Nordisk releases Tresiba long-acting insulin

Novo Nordisk releases Tresiba long-acting insulin

PLAINSBORO, N.J. — Novo Nordisk Inc. has rolled out Tresiba, a once-daily, long-acting basal insulin, to U.S. pharmacies. Novo Nordisk said Tuesday that Tresiba (insulin degludec injection), provides a more flexible option for adults with diabetes who require insulin therapy, who often must plan their schedules to accommodate the need to take insulin at the

Adheris Health